[1]
|
Lindstrom, J.M., Seybold, M.E., Lennon, V.A., Whittingham, S. and Duane, D.D. (1976) Antibody to Acetylcholine Receptor in Myasthenia Gravis. Prevalence, Clinical Correlates, and Diagnostic Value. Neurology, 26, 1054-1059.
https://doi.org/10.1212/WNL.26.11.1054
|
[2]
|
Romi, F., Skeie, G.O., Gilhus, N.E. and Aarli, J.A. (2005) Stria-tional Antibodies in Myasthenia Gravis: Reactivity and Possible Clinical Significance. Archives of Neurology, 62, 442-446. https://doi.org/10.1001/archneur.62.3.442
|
[3]
|
Romi, F., Bø, L., Skeie, G.O., Myking, A., Aarli, J.A. and Gilhus, N.E. (2002) Titin and Ryanodine Receptor Epitopes Are Expressed in Cortical Thymoma along with Costimula-tory Molecules. Journal of Neuroimmunology, 128, 82-89.
https://doi.org/10.1016/S0165-5728(02)00145-5
|
[4]
|
Priola, A.M. and Priola, S.M. (2014) Imaging of Thymus in Myasthenia Gravis: From Thymic Hyperplasia to Thymic Tumor. Clinical Radiology, 69, e230-e245. https://doi.org/10.1016/j.crad.2014.01.005
|
[5]
|
Caballero-Ávila, M., Álvarez-Velasco, R., Moga, E., Rojas-Garcia, R., Turon-Sans, J., Querol, L., et al. (2022) Rituximab in Myasthenia Gravis: Efficacy, Associated Infections and Risk of Induced Hypogammaglobulinemia. Neuromuscular Disorders, 32, 664-671. https://doi.org/10.1016/j.nmd.2022.06.006
|
[6]
|
Jaretzki, A.R., Barohn, R.J., Ernstoff, R.M., Kaminski, H.J., Keesey, J.C., Penn, A.S., et al. (2000) Myasthenia Gravis: Recommendations for Clinical Research Standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. The Annals of Tho-racic Surgery, 70, 327-334.
|
[7]
|
Lazaridis, K. and Tzartos, S.J. (2020) Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. Frontiers in Neurology, 11, Article ID: 596981. https://doi.org/10.3389/fneur.2020.596981
|
[8]
|
王培, 梁文昭, 徐忠信. 重症肌无力血清相关抗体致病机制研究进展[J]. 中风与神经疾病杂志, 2021, 38(11): 1050-1053.
|
[9]
|
Wang, W.W., Hao, H.J. and Gao, F. (2010) Detec-tion of Multiple Antibodies in Myasthenia Gravis and Its Clinical Significance. Chinese Medical Journal (English), 123, 2555-2558.
|
[10]
|
Romi, F., Aarli, J.A. and Gilhus, N.E. (2007) Myasthenia Gravis Patients with Ryanodine Receptor Antibodies Have Distinctive Clinical Features. European Journal of Neurology, 14, 617-620.
https://doi.org/10.1111/j.1468-1331.2007.01785.x
|
[11]
|
Suzuki, S., Utsugisawa, K., Nagane, Y., Satoh, T., Ter-ayama, Y., Suzuki, N., et al. (2007) Classification of Myasthenia Gravis Based on Autoantibody Status. Archives of Neurology, 64, 1121-1124.
https://doi.org/10.1001/archneur.64.8.1121
|
[12]
|
Yildiz, C.S., Durmus, H., Yilmaz, V., Saruhan, D.G., Gulsen, P.Y., Serdaroglu, O.P., et al. (2020) Late-Onset Generalized Myasthenia Gravis: Clinical Features, Treatment, and Out-come. Acta Neurologica Belgica, 120, 133-140.
https://doi.org/10.1007/s13760-019-01252-x
|
[13]
|
Alvarez-Velasco, R., Gutierrez-Gutierrez, G., Trujillo, J.C., Mar-tinez, E., Segovia, S., Arribas-Velasco, M., et al. (2021) Clinical Characteristics and Outcomes of Thymoma-Associated Myasthenia Gravis. European Journal of Neurology, 28, 2083-2091. https://doi.org/10.1111/ene.14820
|
[14]
|
Voltz, R.D., Albrich, W.C., Nagele, A., Schumm, F., Wick, M., Freiburg, A., et al. (1997) Paraneoplastic Myasthenia Gravis: Detection of Anti-MGT30 (Titin) Antibodies Predicts Thymic Epithelial Tumor. Neurology, 49, 1454-1457.
https://doi.org/10.1212/WNL.49.5.1454
|
[15]
|
Hehir, M.K. and Silvestri, N.J. (2018) Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. Neurologic Clinics, 36, 253-260. https://doi.org/10.1016/j.ncl.2018.01.002
|
[16]
|
武翻艳, 肖兴军. 重症肌无力与其他自身免疫性疾病的相关性研究进展[J]. 中国临床神经科学, 2022, 30(3): 338-344.
|
[17]
|
刘云, 郝洪军, 高枫. 伴甲状腺疾病重症肌无力患者的临床特点[J]. 中国神经免疫学和神经病学杂志, 2021, 28(2): 115-119.
|
[18]
|
Chen, Y., Tao, X., Wang, Y., Xu, S., Yang, Y., Han, J., et al. (2022) Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Com-bined with Anti-LRP4 or Anti-Titin Antibody. Frontiers in Neurology, 13, Article ID: 873599. https://doi.org/10.3389/fneur.2022.873599
|
[19]
|
Hong, Y., Li, H.F., Skeie, G.O., Romi, F., Hao, H.J., Zhang, X., et al. (2016) Autoantibody Profile and Clinical Characteristics in a Cohort of Chinese Adult Myasthenia Gravis Patients. Journal of Neuroimmunology, 298, 51-57.
https://doi.org/10.1016/j.jneuroim.2016.07.001
|
[20]
|
Zheng, Y., Yuan, X., Zhang, C., Liu, R., Jin, H., Hao, H., et al. (2022) Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort with Very-Late-Onset Myasthenia Gravis. Frontiers in Neurology, 13, Article ID: 843523.
https://doi.org/10.3389/fneur.2022.843523
|